After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Biosimilars have been quietly moderating drug prices in the background, Bernstein analyst Ronny Gal said in a recent report. Now, armed with their first biosimilar green light of 2021, Biocon and ...

U.S. regulators took action Wednesday that should make it easier to get a cheaper near-copy of a brand-name insulin at the drugstore. Doctors must now prescribe what's called a biosimilar drug, or OK ...